Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
CTNM Stock — Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Updated October 16, 2026.
CTNM is a Stock. Total return is -55.8% over the past 2.5 years, 109.0 points behind SPY at 53.2%.
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drug candidates for neuroscience, inflammation, and immunology conditions. The company's lead program, PIPE-791, targets idiopathic pulmonary fibrosis and chronic pain, while a secondary candidate, PIPE-307, is being evaluated for depression and multiple sclerosis. As an early-stage biotech firm with no approved products, it does not currently distribute income and appeals primarily to investors seeking exposure to developmental pharmaceutical research rather than current income.
CTNM performance versus SPY
Price and return data through 2026-10-16.
Total return is -55.8% over the past 2.5 years, 109.0 points behind SPY at 53.2%. Over the past year its total return — price change plus distributions reinvested — is -43.2%. Its deepest 1-year drawdown was 59.7%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -48.5% | — |
| 3M | -49.5% | — |
| 6M | -46.8% | — |
| YTD | -38.1% | — |
| 1Y | -43.2% | — |
| 2Y CAGR | — | -34.60% |
| Since inception (2.5 years) | -55.8% | -27.50% |
CTNM key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 04/04/2024
- Distribution frequency
- None
- Last close
- $7.08 (as of 2026-10-16)
- Market cap
- $233,347,115
- Average volume
- 1107322.0
- Beta
- 0.856
- Payout ratio
- 0.0%
- EPS
- $-1.75
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
CTNM risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 59.7%.
Who may consider CTNM — and who may not
It is a weaker fit for investors who need monthly cash flow (CTNM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on CTNM
Frequently asked questions
Does CTNM pay monthly?
No. CTNM does not currently distribute.
When does CTNM pay a dividend?
CTNM does not currently distribute.
How has CTNM performed?
Total return is -55.8% over the past 2.5 years, 109.0 points behind SPY at 53.2%. Over the past year its total return — price change plus distributions reinvested — is -43.2%. Its deepest 1-year drawdown was 59.7%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.